Clinical Trial SuccessMultiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Pipeline DevelopmentPositive pipeline updates could attract development partners.
Strategic GrowthManagement is exploring partnership and collaboration options to further develop the program, indicating strategic growth opportunities.